February 1992

Immune Response to Hib Conjugate Vaccine-Reply

Author Affiliations

4650 Sunset Blvd, Box 51 Los Angeles, CA 90027

Am J Dis Child. 1992;146(2):146-147. doi:10.1001/archpedi.1992.02160140012006

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.—Dr Sullivan raises two important considerations when evaluating vaccines in children, immunogenicity and efficacy, ie, protection against invasive Haemophilus influenzae type b disease. Our data demonstrating an inverse relationship of immunogenicity and Haemophilus influenzae type b capsular polysaccharide—Neisseria meningitidis group B outer membrane protein conjugate vaccine (PRP-NOMP) dosage after a second dose of PRP-NOMP cannot directly address the issue of efficacy. We agree that if we were to assume that children achieving anti-PRP antibody levels greater than 1.0 mg/L were protected against H influenzae type b disease, our finding of anti-PRP geometric mean titers of 7.3 mg/L after the second dose of PRP-NOMP in the 30-μg PRP dosage may not be of clinical significance (as stated in our article) because almost all the children achieved anti-PRP antibody levels greater than 1.0 mg/L. The suggestion that "protection in relation to anti-PRP antibody concentration" can be better assessed by comparing age

First Page Preview View Large
First page PDF preview
First page PDF preview